Abbott Laboratories 8-K, filed Oct 21, 2026
Abbott Laboratories (ABT)
8-K
2026-10-21
For: 2026-10-21
View Original
Added on
October 21, 2026
About this 8-K
Abbott Laboratories filed this 8-K on October 21, 2026.
Abbott reported results for the third quarter ended Sept. 30, 2026: sales increased 14.5 percent, comparable sales growth was 7.0 percent, and adjusted diluted EPS was $1.42. Full-year adjusted diluted EPS guidance was $5.50 to $5.55. AI summary
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
_______________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in charter)
_______________________________________________________
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
_______________________________________________________
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (224 ) 667-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities Registered Pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||
NYSE Texas | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition
On October 21, 2026, Abbott Laboratories announced its results of operations for the third quarter 2026.
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal settlements, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01 Financial Statements and Exhibits
| Exhibit No. | Exhibit | |||||||
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABBOTT LABORATORIES | ||||||||
| Date: October 21, 2026 | By: | /s/ Philip P. Boudreau | ||||||
| Philip P. Boudreau | ||||||||
| Executive Vice President, Finance and Chief Financial Officer | ||||||||
| Exhibit 99.1 | |||||
 | News Release | ||||
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
–Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent
–Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42
–Expands portfolio with key new product approvals
ABBOTT PARK, Ill., Oct. 21, 2026 — Abbott today announced financial results for the third quarter ended Sept. 30, 2026.
•Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis.
•Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items.
•Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent1.
•Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55.
•In August, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.
•In August, Abbott announced that the company received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).
•In August, Abbott announced the launch of Similac® 360 Total Care® Made With Whole Milk — the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States.
•In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation.
•In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease.
"Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer, Abbott. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead."
Page 1 of 21
THIRD-QUARTER BUSINESS OVERVIEW
Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions) | Total Company | Nutrition | Diagnostics | Established Pharmaceuticals | Medical Devices | ||||||||||||||||||||||||
| U.S. | 5,504 | 958 | 1,853 | — | 2,687 | ||||||||||||||||||||||||
| International | 7,509 | 1,304 | 1,452 | 1,614 | 3,139 | ||||||||||||||||||||||||
| Total reported | 13,013 | 2,262 | 3,305 | 1,614 | 5,826 | ||||||||||||||||||||||||
| % Change vs. 3Q25 | |||||||||||||||||||||||||||||
| U.S. | 28.0 | 7.9 | 109.2 | n/a | 6.6 | ||||||||||||||||||||||||
| International | 6.2 | 3.1 | 6.2 | 6.8 | 7.2 | ||||||||||||||||||||||||
| Total reported | 14.5 | 5.1 | 46.7 | 6.8 | 6.9 | ||||||||||||||||||||||||
| Total reported excl. foreign exchange impact | 14.8 | 4.9 | 46.6 | 8.4 | 7.4 | ||||||||||||||||||||||||
| Comparable sales growth | 7.0 | 4.9 | 6.4 | 8.4 | 7.8 | ||||||||||||||||||||||||
| U.S. | 7.9 | 7.9 | 8.4 | n/a | 7.6 | ||||||||||||||||||||||||
| International | 6.4 | 2.8 | 4.0 | 8.4 | 8.0 | ||||||||||||||||||||||||
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions) | Total Company | Nutrition | Diagnostics | Established Pharmaceuticals | Medical Devices | ||||||||||||||||||||||||
| U.S. | 14,994 | 2,673 | 4,418 | — | 7,890 | ||||||||||||||||||||||||
| International | 21,776 | 3,750 | 4,159 | 4,539 | 9,328 | ||||||||||||||||||||||||
| Total reported | 36,770 | 6,423 | 8,577 | 4,539 | 17,218 | ||||||||||||||||||||||||
% Change vs. 9M25 | |||||||||||||||||||||||||||||
| U.S. | 17.7 | (4.5) | 72.0 | n/a | 7.1 | ||||||||||||||||||||||||
| International | 8.2 | 1.1 | 6.3 | 9.3 | 11.7 | ||||||||||||||||||||||||
| Total reported | 11.9 | (1.3) | 32.4 | 9.3 | 9.6 | ||||||||||||||||||||||||
| Total reported excl. foreign exchange impact | 10.5 | (2.1) | 30.8 | 8.7 | 7.8 | ||||||||||||||||||||||||
| Comparable sales growth | 5.2 | (2.1) | 3.8 | 8.7 | 8.2 | ||||||||||||||||||||||||
| U.S. | 4.7 | (4.5) | 4.9 | n/a | 8.1 | ||||||||||||||||||||||||
| International | 5.7 | (0.3) | 2.4 | 8.7 | 8.3 | ||||||||||||||||||||||||
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.
Page 2 of 21
Nutrition
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions) | Total | Pediatric | Adult | ||||||||||||||
| U.S. | 958 | 577 | 381 | ||||||||||||||
| International | 1,304 | 486 | 818 | ||||||||||||||
| Total reported | 2,262 | 1,063 | 1,199 | ||||||||||||||
| % Change vs. 3Q25 | |||||||||||||||||
| U.S. | 7.9 | 11.0 | 3.5 | ||||||||||||||
| International | 3.1 | 6.4 | 1.3 | ||||||||||||||
| Total reported | 5.1 | 8.8 | 2.0 | ||||||||||||||
| Total reported excl. foreign exchange impact | 4.9 | 8.7 | 1.8 | ||||||||||||||
| Comparable sales growth | 4.9 | 8.7 | 1.8 | ||||||||||||||
| U.S. | 7.9 | 11.0 | 3.5 | ||||||||||||||
| International | 2.8 | 6.0 | 1.0 | ||||||||||||||
Worldwide Nutrition sales increased 5.1 percent on a reported basis and 4.9 percent on a comparable basis in the third quarter.
Worldwide Nutrition results were driven by broad-based growth across the portfolio, including sales growth of nearly 9.0 percent in Worldwide Pediatric.
On a sequential basis, Worldwide Nutrition sales increased $118 million compared to the second quarter of 2026.
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions) | Total | Pediatric | Adult | ||||||||||||||
| U.S. | 2,673 | 1,613 | 1,060 | ||||||||||||||
| International | 3,750 | 1,428 | 2,322 | ||||||||||||||
| Total reported | 6,423 | 3,041 | 3,382 | ||||||||||||||
% Change vs. 9M25 | |||||||||||||||||
| U.S. | (4.5) | (4.8) | (4.0) | ||||||||||||||
| International | 1.1 | 3.7 | (0.5) | ||||||||||||||
| Total reported | (1.3) | (1.0) | (1.6) | ||||||||||||||
| Total reported excl. foreign exchange impact | (2.1) | (1.6) | (2.6) | ||||||||||||||
| Comparable sales growth | (2.1) | (1.6) | (2.6) | ||||||||||||||
| U.S. | (4.5) | (4.8) | (4.0) | ||||||||||||||
| International | (0.3) | 2.4 | (2.0) | ||||||||||||||
Page 3 of 21
Diagnostics*
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions) | Total | Core Laboratory | Cancer Diagnostics | Rapid/Molecular Diagnostics | |||||||||||||||||||
| U.S. | 1,853 | 389 | 938 | 526 | |||||||||||||||||||
| International | 1,452 | 1,049 | 30 | 373 | |||||||||||||||||||
| Total reported | 3,305 | 1,438 | 968 | 899 | |||||||||||||||||||
| % Change vs. 3Q25 | |||||||||||||||||||||||
| U.S. | 109.2 | 6.3 | n/a | 1.1 | |||||||||||||||||||
| International | 6.2 | 5.1 | n/a | 1.0 | |||||||||||||||||||
| Total reported | 46.7 | 5.4 | n/a | 1.1 | |||||||||||||||||||
| Total reported excl. foreign exchange impact | 46.6 | 5.4 | n/a | 0.9 | |||||||||||||||||||
| Comparable sales growth | 6.4 | 5.4 | 13.8 | 0.9 | |||||||||||||||||||
| U.S. | 8.4 | 6.3 | 13.9 | 1.1 | |||||||||||||||||||
| International | 4.0 | 5.1 | 12.1 | 0.7 | |||||||||||||||||||
Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4 percent on a comparable basis in the third quarter.
Worldwide Core Laboratory Diagnostics results were driven by balanced growth across major geographic regions including the U.S., Europe, Japan, and Latin America.
Cancer Diagnostics results were driven by growth of Cologuard® and also reflect contributions to growth from the precision oncology and international businesses.
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions) | Total | Core Laboratory | Cancer Diagnostics | Rapid/Molecular Diagnostics | |||||||||||||||||||
| U.S. | 4,418 | 1,113 | 1,921 | 1,384 | |||||||||||||||||||
| International | 4,159 | 3,015 | 62 | 1,082 | |||||||||||||||||||
| Total reported | 8,577 | 4,128 | 1,983 | 2,466 | |||||||||||||||||||
% Change vs. 9M25 | |||||||||||||||||||||||
| U.S. | 72.0 | 6.1 | n/a | (8.9) | |||||||||||||||||||
| International | 6.3 | 5.8 | n/a | 1.9 | |||||||||||||||||||
| Total reported | 32.4 | 5.9 | n/a | (4.5) | |||||||||||||||||||
| Total reported excl. foreign exchange impact | 30.8 | 4.0 | n/a | (5.4) | |||||||||||||||||||
| Comparable sales growth | 3.8 | 4.0 | 13.5 | (5.4) | |||||||||||||||||||
| U.S. | 4.9 | 6.1 | 13.5 | (8.9) | |||||||||||||||||||
| International | 2.4 | 3.2 | 15.0 | (0.4) | |||||||||||||||||||
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.
Page 4 of 21
Established Pharmaceuticals
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions) | Total | Key Emerging Markets | Other | ||||||||||||||
| U.S. | — | — | — | ||||||||||||||
| International | 1,614 | 1,195 | 419 | ||||||||||||||
| Total reported | 1,614 | 1,195 | 419 | ||||||||||||||
| % Change vs. 3Q25 | |||||||||||||||||
| U.S. | n/a | n/a | n/a | ||||||||||||||
| International | 6.8 | 9.0 | 1.1 | ||||||||||||||
| Total reported | 6.8 | 9.0 | 1.1 | ||||||||||||||
| Total reported excl. foreign exchange impact | 8.4 | 10.9 | 1.6 | ||||||||||||||
| Comparable sales growth | 8.4 | 10.9 | 1.6 | ||||||||||||||
| U.S. | n/a | n/a | n/a | ||||||||||||||
| International | 8.4 | 10.9 | 1.6 | ||||||||||||||
Established Pharmaceuticals sales increased 6.8 percent on a reported basis and 8.4 percent on a comparable basis in the third quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.0 percent on a reported basis and 10.9 percent on a comparable basis, led by double-digit growth in India and several markets across the Latin America and Asia Pacific regions.
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions) | Total | Key Emerging Markets | Other | ||||||||||||||
| U.S. | — | — | — | ||||||||||||||
| International | 4,539 | 3,448 | 1,091 | ||||||||||||||
| Total reported | 4,539 | 3,448 | 1,091 | ||||||||||||||
% Change vs. 9M25 | |||||||||||||||||
| U.S. | n/a | n/a | n/a | ||||||||||||||
| International | 9.3 | 10.5 | 5.6 | ||||||||||||||
| Total reported | 9.3 | 10.5 | 5.6 | ||||||||||||||
| Total reported excl. foreign exchange impact | 8.7 | 10.4 | 3.6 | ||||||||||||||
| Comparable sales growth | 8.7 | 10.4 | 3.6 | ||||||||||||||
| U.S. | n/a | n/a | n/a | ||||||||||||||
| International | 8.7 | 10.4 | 3.6 | ||||||||||||||
Page 5 of 21
Medical Devices
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions) | Total | Rhythm Management | Electro-physiology* | Heart Failure | Vascular | Structural Heart* | Neuro-modulation | Diabetes Care | |||||||||||||||||||||||||||||||||||||||
| U.S. | 2,687 | 380 | 429 | 303 | 290 | 228 | 185 | 872 | |||||||||||||||||||||||||||||||||||||||
| International | 3,139 | 372 | 444 | 84 | 496 | 364 | 66 | 1,313 | |||||||||||||||||||||||||||||||||||||||
| Total reported | 5,826 | 752 | 873 | 387 | 786 | 592 | 251 | 2,185 | |||||||||||||||||||||||||||||||||||||||
| % Change vs. 3Q25 | |||||||||||||||||||||||||||||||||||||||||||||||
| U.S. | 6.6 | 9.0 | 18.1 | 8.4 | 3.4 | (11.1) | (5.6) | 9.4 | |||||||||||||||||||||||||||||||||||||||
| International | 7.2 | 10.4 | 12.2 | (2.7) | 6.7 | 12.2 | 13.6 | 4.2 | |||||||||||||||||||||||||||||||||||||||
| Total reported | 6.9 | 9.7 | 15.0 | 5.8 | 5.4 | 1.9 | (1.2) | 6.2 | |||||||||||||||||||||||||||||||||||||||
| Total reported excl. foreign exchange impact | 7.4 | 10.0 | 15.5 | 6.0 | 5.7 | 2.6 | (1.1) | 6.7 | |||||||||||||||||||||||||||||||||||||||
| Comparable sales growth | 7.8 | 10.0 | 15.5 | 6.0 | 5.7 | 6.9 | (1.1) | 6.7 | |||||||||||||||||||||||||||||||||||||||
| U.S. | 7.6 | 9.0 | 18.1 | 8.4 | 3.4 | (2.3) | (5.6) | 9.4 | |||||||||||||||||||||||||||||||||||||||
| International | 8.0 | 11.0 | 13.1 | (1.6) | 7.1 | 13.5 | 13.9 | 4.9 | |||||||||||||||||||||||||||||||||||||||
Worldwide Medical Devices sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis in the third quarter.
Sales growth in the quarter was led by double-digit growth in Electrophysiology and Rhythm Management.
In Diabetes Care, sales of continuous glucose monitors grew 7.3 percent on a reported basis and 7.7 percent on a comparable basis.
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions) | Total | Rhythm Management | Electro-physiology* | Heart Failure | Vascular | Structural Heart* | Neuro-modulation | Diabetes Care | |||||||||||||||||||||||||||||||||||||||
| U.S. | 7,890 | 1,096 | 1,227 | 908 | 875 | 677 | 551 | 2,556 | |||||||||||||||||||||||||||||||||||||||
| International | 9,328 | 1,083 | 1,295 | 269 | 1,491 | 1,090 | 203 | 3,897 | |||||||||||||||||||||||||||||||||||||||
| Total reported | 17,218 | 2,179 | 2,522 | 1,177 | 2,366 | 1,767 | 754 | 6,453 | |||||||||||||||||||||||||||||||||||||||
% Change vs. 9M25 | |||||||||||||||||||||||||||||||||||||||||||||||
| U.S. | 7.1 | 10.4 | 16.0 | 10.2 | 5.2 | (10.2) | (2.4) | 9.3 | |||||||||||||||||||||||||||||||||||||||
| International | 11.7 | 13.9 | 14.5 | 7.9 | 8.0 | 16.1 | 18.1 | 10.5 | |||||||||||||||||||||||||||||||||||||||
| Total reported | 9.6 | 12.1 | 15.2 | 9.7 | 7.0 | 4.4 | 2.4 | 10.0 | |||||||||||||||||||||||||||||||||||||||
| Total reported excl. foreign exchange impact | 7.8 | 10.6 | 13.8 | 8.9 | 5.2 | 2.6 | 1.3 | 7.7 | |||||||||||||||||||||||||||||||||||||||
| Comparable sales growth | 8.2 | 10.6 | 13.8 | 8.9 | 5.2 | 6.5 | 1.3 | 7.7 | |||||||||||||||||||||||||||||||||||||||
| U.S. | 8.1 | 10.4 | 16.0 | 10.2 | 5.2 | (2.3) | (2.4) | 9.3 | |||||||||||||||||||||||||||||||||||||||
| International | 8.3 | 10.8 | 11.9 | 4.6 | 5.2 | 12.8 | 13.5 | 6.6 | |||||||||||||||||||||||||||||||||||||||
*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 and $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.
Page 6 of 21
Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth to be approximately 6.0%1.
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.
Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.
Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.
Abbott Declares 411th Consecutive Quarterly Dividend
On Sept. 17, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.
Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
Page 7 of 21
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Abbott Financial: Michael Comilla, 224-668-1872 Tamika McLoughlin, 224-399-5082 Randy Blakley, 224-668-0036 | Abbott Media: Karen Twigg May, 224-668-2681 Kate Dyer, 224-668-9965 | ||||
1.In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million.
Page 8 of 21
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Third Quarter Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
| 3Q26 | 3Q25 | % Change | ||||||||||||||||||
| Net Sales | $13,013 | $11,369 | 14.5 | |||||||||||||||||
| Cost of products sold, excluding amortization expense | 5,628 | 5,075 | 10.9 | |||||||||||||||||
| Amortization of intangible assets | 841 | 420 | n/m | |||||||||||||||||
| Research and development | 920 | 766 | 20.1 | |||||||||||||||||
| Selling, general, and administrative | 4,266 | 3,051 | 39.8 | |||||||||||||||||
| Total Operating Cost and Expenses | 11,655 | 9,312 | 25.2 | |||||||||||||||||
| Operating Earnings | 1,358 | 2,057 | (34.0) | |||||||||||||||||
| Interest expense, net | 297 | 44 | n/m | |||||||||||||||||
| Net foreign exchange (gain) loss | (6) | (17) | n/m | |||||||||||||||||
| Other (income) expense, net | (164) | (150) | 9.4 | |||||||||||||||||
| Earnings before taxes | 1,231 | 2,180 | (43.5) | |||||||||||||||||
| Taxes on Earnings | 311 | 536 | (42.0) | 1) | ||||||||||||||||
| Net Earnings | $920 | $1,644 | (44.1) | |||||||||||||||||
| Net Earnings excluding Specified Items, as described below | $2,477 | $2,278 | 8.7 | 2) | ||||||||||||||||
| Diluted Earnings per Common Share | $0.53 | $0.94 | (43.6) | |||||||||||||||||
| Diluted Earnings per Common Share, excluding Specified Items, as described below | $1.42 | $1.30 | 9.2 | 2) | ||||||||||||||||
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,738 | 1,749 | ||||||||||||||||||
NOTES:
See tables on page 13 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
Page 9 of 21
1)2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.557 billion, or $0.89 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $634 million, or $0.36 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.
Page 10 of 21
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Nine Months Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
| 9M26 | 9M25 | % Change | ||||||||||||||||||
| Net Sales | $36,770 | $32,869 | 11.9 | |||||||||||||||||
| Cost of products sold, excluding amortization expense | 15,843 | 14,397 | 10.0 | |||||||||||||||||
| Amortization of intangible assets | 1,921 | 1,260 | 52.4 | |||||||||||||||||
| Research and development | 2,579 | 2,207 | 16.9 | |||||||||||||||||
| Selling, general, and administrative | 12,031 | 9,203 | 30.7 | |||||||||||||||||
| Total Operating Cost and Expenses | 32,374 | 27,067 | 19.6 | |||||||||||||||||
| Operating Earnings | 4,396 | 5,802 | (24.2) | |||||||||||||||||
| Interest expense, net | 664 | 143 | n/m | |||||||||||||||||
| Net foreign exchange (gain) loss | (15) | (35) | n/m | |||||||||||||||||
| Other (income) expense, net | (457) | (414) | 10.2 | |||||||||||||||||
| Earnings before taxes | 4,204 | 6,108 | (31.2) | |||||||||||||||||
| Taxes on earnings | 1,279 | 1,360 | (6.0) | 1) | ||||||||||||||||
| Net Earnings | $2,925 | $4,748 | (38.4) | |||||||||||||||||
| Net Earnings excluding Specified Items, as described below | $6,789 | $6,410 | 5.9 | 2) | ||||||||||||||||
| Diluted Earnings per Common Share | $1.67 | $2.70 | (38.1) | |||||||||||||||||
| Diluted Earnings per Common Share, excluding Specified Items, as described below | $3.88 | $3.65 | 6.3 | 2) | ||||||||||||||||
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,743 | 1,749 | ||||||||||||||||||
NOTES:
See tables on page 14 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
Page 11 of 21
1)2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $3.864 billion, or $2.21 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.662 billion, or $0.95 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.
Page 12 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Third Quarter Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
| 3Q26 | |||||||||||||||||||||||
| As Reported (GAAP) | Specified Items | As Adjusted | |||||||||||||||||||||
Intangible Amortization | $ | 841 | $ | (841) | $ | — | |||||||||||||||||
Gross Margin | 6,544 | 904 | 7,448 | ||||||||||||||||||||
R&D | 920 | (28) | 892 | ||||||||||||||||||||
SG&A | 4,266 | (761) | 3,505 | ||||||||||||||||||||
Other (income) expense, net | (164) | 4 | (160) | ||||||||||||||||||||
Earnings before taxes | 1,231 | 1,689 | 2,920 | ||||||||||||||||||||
Taxes on Earnings | 311 | 132 | 443 | ||||||||||||||||||||
Net Earnings | 920 | 1,557 | 2,477 | ||||||||||||||||||||
Diluted Earnings per Share | $ | 0.53 | $ | 0.89 | $ | 1.42 | |||||||||||||||||
Specified items reflect intangible amortization expense of $841 million, legal settlements of approximately $670 million and other net expenses of $178 million associated with acquisitions, restructuring actions, and other net expenses. See page 18 for additional details regarding specified items.
| 3Q25 | |||||||||||||||||||||||
| As Reported (GAAP) | Specified Items | As Adjusted | |||||||||||||||||||||
Intangible Amortization | $ | 420 | $ | (420) | $ | — | |||||||||||||||||
Gross Margin | 5,874 | 470 | 6,344 | ||||||||||||||||||||
R&D | 766 | (36) | 730 | ||||||||||||||||||||
SG&A | 3,051 | (47) | 3,004 | ||||||||||||||||||||
Other (income) expense, net | (150) | 5 | (145) | ||||||||||||||||||||
Earnings before taxes | 2,180 | 548 | 2,728 | ||||||||||||||||||||
Taxes on Earnings | 536 | (86) | 450 | ||||||||||||||||||||
Net Earnings | 1,644 | 634 | 2,278 | ||||||||||||||||||||
Diluted Earnings per Share | $ | 0.94 | $ | 0.36 | $ | 1.30 | |||||||||||||||||
Specified items reflect intangible amortization expense of $420 million and other net expenses of $128 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See page 19 for additional details regarding specified items.
Page 13 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Nine Months Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
| 9M26 | |||||||||||||||||||||||
| As Reported (GAAP) | Specified Items | As Adjusted | |||||||||||||||||||||
Intangible Amortization | $ | 1,921 | $ | (1,921) | $ | — | |||||||||||||||||
Gross Margin | 19,006 | 2,033 | 21,039 | ||||||||||||||||||||
R&D | 2,579 | (77) | 2,502 | ||||||||||||||||||||
SG&A | 12,031 | (1,662) | 10,369 | ||||||||||||||||||||
Other (income) expense, net | (457) | (30) | (487) | ||||||||||||||||||||
Earnings before taxes | 4,204 | 3,802 | 8,006 | ||||||||||||||||||||
Taxes on Earnings | 1,279 | (62) | 1,217 | ||||||||||||||||||||
Net Earnings | 2,925 | 3,864 | 6,789 | ||||||||||||||||||||
Diluted Earnings per Share | $ | 1.67 | $ | 2.21 | $ | 3.88 | |||||||||||||||||
Specified items reflect intangible amortization expense of $1.921 billion, legal settlements of approximately $1.070 billion and other net expenses of $811 million associated with acquisitions, restructuring actions, and other net expenses. See page 20 for additional details regarding specified items.
| 9M25 | |||||||||||||||||||||||
| As Reported (GAAP) | Specified Items | As Adjusted | |||||||||||||||||||||
Intangible Amortization | $ | 1,260 | $ | (1,260) | $ | — | |||||||||||||||||
Gross Margin | 17,212 | 1,396 | 18,608 | ||||||||||||||||||||
R&D | 2,207 | (83) | 2,124 | ||||||||||||||||||||
SG&A | 9,203 | (58) | 9,145 | ||||||||||||||||||||
Other (income) expense, net | (414) | (31) | (445) | ||||||||||||||||||||
Earnings before taxes | 6,108 | 1,568 | 7,676 | ||||||||||||||||||||
Taxes on Earnings | 1,360 | (94) | 1,266 | ||||||||||||||||||||
Net Earnings | 4,748 | 1,662 | 6,410 | ||||||||||||||||||||
Diluted Earnings per Share | $ | 2.70 | $ | 0.95 | $ | 3.65 | |||||||||||||||||
Specified items reflect intangible amortization expense of $1.260 billion and other net expenses of $308 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See page 21 for additional details regarding specified items.
Page 14 of 21
A reconciliation of the third-quarter tax rates for 2026 and 2025 is shown below:
| 3Q26 | ||||||||||||||||||||
| ($ in millions) | Pre-Tax Income | Taxes on Earnings | Tax Rate | |||||||||||||||||
| As reported (GAAP) | $ | 1,231 | $ | 311 | 25.3 | % | 1) | |||||||||||||
| Specified items | 1,689 | 132 | ||||||||||||||||||
| Excluding specified items | $ | 2,920 | $ | 443 | 15.2 | % | ||||||||||||||
| 3Q25 | ||||||||||||||||||||
| ($ in millions) | Pre-Tax Income | Taxes on Earnings | Tax Rate | |||||||||||||||||
| As reported (GAAP) | $ | 2,180 | $ | 536 | 24.6 | % | 2) | |||||||||||||
| Specified items | 548 | (86) | ||||||||||||||||||
| Excluding specified items | $ | 2,728 | $ | 450 | 16.5 | % | ||||||||||||||
1)2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below:
| 9M26 | ||||||||||||||||||||
| ($ in millions) | Pre-Tax Income | Taxes on Earnings | Tax Rate | |||||||||||||||||
| As reported (GAAP) | $ | 4,204 | $ | 1,279 | 30.4 | % | 3) | |||||||||||||
| Specified items | 3,802 | (62) | ||||||||||||||||||
| Excluding specified items | $ | 8,006 | $ | 1,217 | 15.2 | % | ||||||||||||||
| 9M25 | ||||||||||||||||||||
| ($ in millions) | Pre-Tax Income | Taxes on Earnings | Tax Rate | |||||||||||||||||
| As reported (GAAP) | $ | 6,108 | $ | 1,360 | 22.3 | % | 4) | |||||||||||||
| Specified items | 1,568 | (94) | ||||||||||||||||||
| Excluding specified items | $ | 7,676 | $ | 1,266 | 16.5 | % | ||||||||||||||
3)2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
4)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 15 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Third Quarter Ended September 30, 2026 and 2025
($ in millions)
(unaudited)
| 3Q26 | 3Q25 | % Change vs. 3Q25 | ||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP | ||||||||||||||||||||||||||||||||||||||||||||
| Abbott Reported | Foreign exchange | Comparable Revenue | Abbott Reported | Impact of acquisition (a) | Impact of multi-year agreement (b) | Comparable Revenue | Reported | Comparable | ||||||||||||||||||||||||||||||||||||
| Total Company | 13,013 | 40 | 13,053 | 11,369 | 851 | (23) | 12,197 | 14.5 | 7.0 | |||||||||||||||||||||||||||||||||||
| U.S. | 5,504 | — | 5,504 | 4,299 | 824 | (23) | 5,100 | 28.0 | 7.9 | |||||||||||||||||||||||||||||||||||
| Intl | 7,509 | 40 | 7,549 | 7,070 | 27 | — | 7,097 | 6.2 | 6.4 | |||||||||||||||||||||||||||||||||||
| Total Diagnostics | 3,305 | (2) | 3,303 | 2,253 | 851 | — | 3,104 | 46.7 | 6.4 | |||||||||||||||||||||||||||||||||||
| U.S. | 1,853 | — | 1,853 | 886 | 824 | — | 1,710 | 109.2 | 8.4 | |||||||||||||||||||||||||||||||||||
| Intl | 1,452 | (2) | 1,450 | 1,367 | 27 | — | 1,394 | 6.2 | 4.0 | |||||||||||||||||||||||||||||||||||
| Total Cancer Diagnostics | 968 | — | 968 | — | 851 | — | 851 | n/a | 13.8 | |||||||||||||||||||||||||||||||||||
| U.S. | 938 | — | 938 | — | 824 | — | 824 | n/a | 13.9 | |||||||||||||||||||||||||||||||||||
| Intl | 30 | — | 30 | — | 27 | — | 27 | n/a | 12.1 | |||||||||||||||||||||||||||||||||||
| Total Medical Devices | 5,826 | 22 | 5,848 | 5,448 | — | (23) | 5,425 | 6.9 | 7.8 | |||||||||||||||||||||||||||||||||||
| U.S. | 2,687 | — | 2,687 | 2,521 | — | (23) | 2,498 | 6.6 | 7.6 | |||||||||||||||||||||||||||||||||||
| Intl | 3,139 | 22 | 3,161 | 2,927 | — | — | 2,927 | 7.2 | 8.0 | |||||||||||||||||||||||||||||||||||
| Total Structural Heart* | 592 | 4 | 596 | 580 | — | (23) | 557 | 1.9 | 6.9 | |||||||||||||||||||||||||||||||||||
| U.S. | 228 | — | 228 | 256 | — | (23) | 233 | (11.1) | (2.3) | |||||||||||||||||||||||||||||||||||
| Intl | 364 | 4 | 368 | 324 | — | — | 324 | 12.2 | 13.5 | |||||||||||||||||||||||||||||||||||
| * | Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 were moved from Structural Heart to Electrophysiology. | ||||
| a) | The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026. | ||||
| b) | Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026. | ||||
Page 16 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Nine Months Ended September 30, 2026 and 2025
($ in millions)
(unaudited)
| 9M26 | 9M25 | % Change vs. 9M25 | ||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP | ||||||||||||||||||||||||||||||||||||||||||||
| Abbott Reported | Impact of acquisition (a) | Impact of multi-year agreement (b) | Foreign exchange | Comparable Revenue | Abbott Reported | Impact of acquisition (a) | Impact of multi-year agreement (b) | Comparable Revenue | Reported | Comparable | ||||||||||||||||||||||||||||||||||
| Total Company | 36,770 | 706 | (8) | (460) | 37,008 | 32,869 | 2,369 | (69) | 35,169 | 11.9 | 5.2 | |||||||||||||||||||||||||||||||||
| U.S. | 14,994 | 681 | (8) | — | 15,667 | 12,743 | 2,294 | (69) | 14,968 | 17.7 | 4.7 | |||||||||||||||||||||||||||||||||
| Intl | 21,776 | 25 | — | (460) | 21,341 | 20,126 | 75 | — | 20,201 | 8.2 | 5.7 | |||||||||||||||||||||||||||||||||
| Total Diagnostics | 8,577 | 706 | — | (100) | 9,183 | 6,480 | 2,369 | — | 8,849 | 32.4 | 3.8 | |||||||||||||||||||||||||||||||||
| U.S. | 4,418 | 681 | — | — | 5,099 | 2,568 | 2,294 | — | 4,862 | 72.0 | 4.9 | |||||||||||||||||||||||||||||||||
| Intl | 4,159 | 25 | — | (100) | 4,084 | 3,912 | 75 | — | 3,987 | 6.3 | 2.4 | |||||||||||||||||||||||||||||||||
| Total Cancer Diagnostics | 1,983 | 706 | — | (1) | 2,688 | — | 2,369 | — | 2,369 | n/a | 13.5 | |||||||||||||||||||||||||||||||||
| U.S. | 1,921 | 681 | — | — | 2,602 | — | 2,294 | — | 2,294 | n/a | 13.5 | |||||||||||||||||||||||||||||||||
| Intl | 62 | 25 | — | (1) | 86 | — | 75 | — | 75 | n/a | 15.0 | |||||||||||||||||||||||||||||||||
| Total Medical Devices | 17,218 | — | (8) | (284) | 16,926 | 15,712 | — | (69) | 15,643 | 9.6 | 8.2 | |||||||||||||||||||||||||||||||||
| U.S. | 7,890 | — | (8) | — | 7,882 | 7,363 | — | (69) | 7,294 | 7.1 | 8.1 | |||||||||||||||||||||||||||||||||
| Intl | 9,328 | — | — | (284) | 9,044 | 8,349 | — | — | 8,349 | 11.7 | 8.3 | |||||||||||||||||||||||||||||||||
| Total Structural Heart* | 1,767 | — | (8) | (31) | 1,728 | 1,692 | — | (69) | 1,623 | 4.4 | 6.5 | |||||||||||||||||||||||||||||||||
| U.S. | 677 | — | (8) | — | 669 | 753 | — | (69) | 684 | (10.2) | (2.3) | |||||||||||||||||||||||||||||||||
| Intl | 1,090 | — | — | (31) | 1,059 | 939 | — | — | 939 | 16.1 | 12.8 | |||||||||||||||||||||||||||||||||
| * | Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology. | ||||
| a) | The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026. | ||||
| b) | Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026. | ||||
Page 17 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Third Quarter Ended September 30, 2026
(in millions, except per share data)
(unaudited)
| Acquisition or Divestiture- related (a) | Restructuring and Cost Reduction Initiatives (b) | Intangible Amortization | Other (c) | Total Specifieds | |||||||||||||||||||||||||
| Gross Margin | $ | 10 | $ | 29 | $ | 841 | $ | 24 | $ | 904 | |||||||||||||||||||
| R&D | (7) | (5) | — | (16) | (28) | ||||||||||||||||||||||||
| SG&A | (47) | (20) | — | (694) | (761) | ||||||||||||||||||||||||
| Other (income) expense, net | (8) | (1) | — | 13 | 4 | ||||||||||||||||||||||||
| Earnings before taxes | $ | 72 | $ | 55 | $ | 841 | $ | 721 | 1,689 | ||||||||||||||||||||
| Taxes on Earnings (d) | 132 | ||||||||||||||||||||||||||||
| Net Earnings | $ | 1,557 | |||||||||||||||||||||||||||
| Diluted Earnings per Share | $ | 0.89 | |||||||||||||||||||||||||||
The table above provides additional details regarding the specified items described on page 13.
a)Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.
c)Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants, as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 18 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Third Quarter Ended September 30, 2025
(in millions, except per share data)
(unaudited)
| Acquisition or Divestiture- related (a) | Restructuring and Cost Reduction Initiatives (b) | Intangible Amortization | Other (c) | Total Specifieds | |||||||||||||||||||||||||
| Gross Margin | $ | — | $ | 44 | $ | 420 | $ | 6 | $ | 470 | |||||||||||||||||||
| R&D | — | (19) | — | (17) | (36) | ||||||||||||||||||||||||
| SG&A | (9) | (43) | — | 5 | (47) | ||||||||||||||||||||||||
| Other (income) expense, net | 7 | — | — | (2) | 5 | ||||||||||||||||||||||||
| Earnings before taxes | $ | 2 | $ | 106 | $ | 420 | $ | 20 | 548 | ||||||||||||||||||||
| Taxes on Earnings (d) | (86) | ||||||||||||||||||||||||||||
| Net Earnings | $ | 634 | |||||||||||||||||||||||||||
| Diluted Earnings per Share | $ | 0.36 | |||||||||||||||||||||||||||
The table above provides additional details regarding the specified items described on page 13.
a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)Reflects the net tax benefit associated with the specified items. Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 19 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Nine Months Ended September 30, 2026
(in millions, except per share data)
(unaudited)
| Acquisition or Divestiture- related (a) | Restructuring and Cost Reduction Initiatives (b) | Intangible Amortization | Other (c) | Total Specifieds | |||||||||||||||||||||||||
| Gross Margin | $ | 44 | $ | 40 | $ | 1,921 | $ | 28 | $ | 2,033 | |||||||||||||||||||
| R&D | (18) | (15) | — | (44) | (77) | ||||||||||||||||||||||||
| SG&A | (533) | (54) | — | (1,075) | (1,662) | ||||||||||||||||||||||||
| Other (income) expense, net | (9) | (4) | — | (17) | (30) | ||||||||||||||||||||||||
| Earnings before taxes | $ | 604 | $ | 113 | $ | 1,921 | $ | 1,164 | 3,802 | ||||||||||||||||||||
| Taxes on Earnings (d) | (62) | ||||||||||||||||||||||||||||
| Net Earnings | $ | 3,864 | |||||||||||||||||||||||||||
| Diluted Earnings per Share | $ | 2.21 | |||||||||||||||||||||||||||
The table above provides additional details regarding the specified items described on page 14.
a)Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.
c)Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the NEC claims asserted on behalf of approximately 2,000 additional infants; approximately $400 million, including attorneys' fees and accrued interest, related to an agreement to resolve the United States Department of Justice (DOJ) investigations and the civil qui tam lawsuit brought by certain relators and joined by the DOJ and Attorneys General of several states; as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 20 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Nine Months Ended September 30, 2025
(in millions, except per share data)
(unaudited)
| Acquisition or Divestiture- related (a) | Restructuring and Cost Reduction Initiatives (b) | Intangible Amortization | Other (c) | Total Specifieds | |||||||||||||||||||||||||
| Gross Margin | $ | 1 | $ | 125 | $ | 1,260 | $ | 10 | $ | 1,396 | |||||||||||||||||||
| R&D | (1) | (42) | — | (40) | (83) | ||||||||||||||||||||||||
| SG&A | (15) | (49) | — | 6 | (58) | ||||||||||||||||||||||||
| Other (income) expense, net | (18) | — | — | (13) | (31) | ||||||||||||||||||||||||
| Earnings before taxes | $ | 35 | $ | 216 | $ | 1,260 | $ | 57 | 1,568 | ||||||||||||||||||||
| Taxes on Earnings (d) | (94) | ||||||||||||||||||||||||||||
| Net Earnings | $ | 1,662 | |||||||||||||||||||||||||||
| Diluted Earnings per Share | $ | 0.95 | |||||||||||||||||||||||||||
The table above provides additional details regarding the specified items described on page 14.
a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.
d)Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 21 of 21